Skybiotech Healthcare Limited (BOM:512036)
India · Delayed Price · Currency is INR 120.00
-0.80 (-0.66%)
At close: Sep 15, 2026
Skybiotech Healthcare Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 52.03 | 70.98 | 70.52 | - | - | - |
Other Revenue | 3.32 | 0.73 | 2.22 | 20.02 | 0.54 | 0.23 |
| 55.35 | 71.71 | 72.74 | 20.02 | 0.54 | 0.23 | |
Revenue Growth | -41.76% | -1.41% | 263.26% | 3597.53% | 138.36% | 16.26% |
Cost of Revenue | 29.93 | 40.82 | 37.73 | - | - | - |
Gross Profit | 25.42 | 30.89 | 35.01 | 20.02 | 0.54 | 0.23 |
Selling, General & Admin | 17.59 | 17.65 | 19.63 | 0.19 | 0.12 | 0.16 |
Other Operating Expenses | 25.22 | 27.04 | 34.1 | 1.08 | 0.48 | 0.43 |
Operating Expenses | 47.45 | 49.47 | 59.14 | 1.27 | 0.62 | 0.61 |
Operating Income | -22.04 | -18.58 | -24.14 | 18.75 | -0.07 | -0.38 |
Interest Expense | -0.18 | -0.15 | - | - | - | - |
Interest & Investment Income | - | - | 0.01 | - | - | - |
Currency Exchange Gain (Loss) | - | - | -0.01 | - | - | - |
Other Non Operating Income (Expenses) | - | 2.08 | -0.12 | -0 | - | - |
EBT Excluding Unusual Items | -22.22 | -16.65 | -24.26 | 18.75 | -0.07 | -0.38 |
Asset Writedown | - | -0.02 | - | - | - | - |
Pretax Income | -22.22 | -16.67 | -24.26 | 18.75 | -0.07 | -0.38 |
Income Tax Expense | -5.5 | -5.5 | -0.57 | 3.4 | -0 | 0 |
Net Income | -16.72 | -11.17 | -23.69 | 15.35 | -0.07 | -0.38 |
Net Income to Common | -16.72 | -11.17 | -23.69 | 15.35 | -0.07 | -0.38 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 1 | 1 |
Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 1 | 1 |
Shares Change | - | -0.22% | -12.76% | 84.14% | - | - |
EPS (Basic) | -7.46 | -6.70 | -14.18 | 8.02 | -0.07 | -0.36 |
EPS (Diluted) | -7.46 | -6.70 | -14.18 | 8.02 | -0.07 | -0.36 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -15.18 | -13.68 | -13.37 | -3.73 | 6.1 |
Free Cash Flow Per Share | - | -9.11 | -8.19 | -6.98 | -3.59 | 5.86 |
Gross Margin | 45.92% | 43.08% | 48.13% | 100.00% | 100.00% | 100.00% |
Operating Margin | -39.82% | -25.91% | -33.18% | 93.64% | -13.62% | -166.50% |
Profit Margin | -30.20% | -15.57% | -32.57% | 76.68% | -13.37% | -166.58% |
Free Cash Flow Margin | - | -21.17% | -18.80% | -66.76% | -688.68% | 2683.86% |
EBITDA | -17.41 | -13.79 | -18.72 | 18.76 | -0.06 | -0.36 |
EBITDA Margin | -31.45% | -19.23% | -25.74% | 93.68% | -10.83% | -156.29% |
D&A For EBITDA | 4.63 | 4.79 | 5.42 | 0.01 | 0.02 | 0.02 |
EBIT | -22.04 | -18.58 | -24.14 | 18.75 | -0.07 | -0.38 |
EBIT Margin | -39.82% | -25.91% | -33.18% | 93.64% | -13.62% | -166.50% |
Effective Tax Rate | - | - | - | 18.12% | - | - |
Revenue as Reported | 55.35 | 74.04 | 74.35 | 20.02 | 0.54 | 0.23 |
Advertising Expenses | - | 0.02 | - | 0.04 | 0.01 | 0.01 |